Cargando…
Anti-VEGF Therapy and the Retina: An Update
Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial gro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568374/ https://www.ncbi.nlm.nih.gov/pubmed/26417453 http://dx.doi.org/10.1155/2015/627674 |
_version_ | 1782389900373393408 |
---|---|
author | Tah, Vikas Orlans, Harry O. Hyer, Jonathan Casswell, Edward Din, Nizar Sri Shanmuganathan, Vishnu Ramskold, Louise Pasu, Saruban |
author_facet | Tah, Vikas Orlans, Harry O. Hyer, Jonathan Casswell, Edward Din, Nizar Sri Shanmuganathan, Vishnu Ramskold, Louise Pasu, Saruban |
author_sort | Tah, Vikas |
collection | PubMed |
description | Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients. |
format | Online Article Text |
id | pubmed-4568374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-45683742015-09-28 Anti-VEGF Therapy and the Retina: An Update Tah, Vikas Orlans, Harry O. Hyer, Jonathan Casswell, Edward Din, Nizar Sri Shanmuganathan, Vishnu Ramskold, Louise Pasu, Saruban J Ophthalmol Review Article Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients. Hindawi Publishing Corporation 2015 2015-08-31 /pmc/articles/PMC4568374/ /pubmed/26417453 http://dx.doi.org/10.1155/2015/627674 Text en Copyright © 2015 Vikas Tah et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Tah, Vikas Orlans, Harry O. Hyer, Jonathan Casswell, Edward Din, Nizar Sri Shanmuganathan, Vishnu Ramskold, Louise Pasu, Saruban Anti-VEGF Therapy and the Retina: An Update |
title | Anti-VEGF Therapy and the Retina: An Update |
title_full | Anti-VEGF Therapy and the Retina: An Update |
title_fullStr | Anti-VEGF Therapy and the Retina: An Update |
title_full_unstemmed | Anti-VEGF Therapy and the Retina: An Update |
title_short | Anti-VEGF Therapy and the Retina: An Update |
title_sort | anti-vegf therapy and the retina: an update |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568374/ https://www.ncbi.nlm.nih.gov/pubmed/26417453 http://dx.doi.org/10.1155/2015/627674 |
work_keys_str_mv | AT tahvikas antivegftherapyandtheretinaanupdate AT orlansharryo antivegftherapyandtheretinaanupdate AT hyerjonathan antivegftherapyandtheretinaanupdate AT casswelledward antivegftherapyandtheretinaanupdate AT dinnizar antivegftherapyandtheretinaanupdate AT srishanmuganathanvishnu antivegftherapyandtheretinaanupdate AT ramskoldlouise antivegftherapyandtheretinaanupdate AT pasusaruban antivegftherapyandtheretinaanupdate |